AR123512A1 - Conjugados terapéuticos - Google Patents

Conjugados terapéuticos

Info

Publication number
AR123512A1
AR123512A1 ARP210102551A ARP210102551A AR123512A1 AR 123512 A1 AR123512 A1 AR 123512A1 AR P210102551 A ARP210102551 A AR P210102551A AR P210102551 A ARP210102551 A AR P210102551A AR 123512 A1 AR123512 A1 AR 123512A1
Authority
AR
Argentina
Prior art keywords
therapeutic conjugates
therapeutic
formula
conjugates
conjugate
Prior art date
Application number
ARP210102551A
Other languages
English (en)
Inventor
Neil Sonin Dhawan
James Abellera Blair
Robert B Perni
Original Assignee
Totus Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Totus Medicines Inc filed Critical Totus Medicines Inc
Publication of AR123512A1 publication Critical patent/AR123512A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01042—Isocitrate dehydrogenase (NADP+) (1.1.1.42)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 4: El conjugado terapéutico de acuerdo con la reivindicación 2, caracterizado porque el conjugado tiene una estructura de fórmula (1), en donde R es H o un grupo alquilo, o de fórmula (2).
ARP210102551A 2020-09-14 2021-09-14 Conjugados terapéuticos AR123512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063078052P 2020-09-14 2020-09-14

Publications (1)

Publication Number Publication Date
AR123512A1 true AR123512A1 (es) 2022-12-07

Family

ID=80630057

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102551A AR123512A1 (es) 2020-09-14 2021-09-14 Conjugados terapéuticos

Country Status (5)

Country Link
US (1) US20230405135A1 (es)
EP (1) EP4210766A1 (es)
AR (1) AR123512A1 (es)
TW (1) TW202227138A (es)
WO (1) WO2022056453A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355945B (es) * 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CN108026052B (zh) * 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
US10137130B2 (en) * 2016-02-26 2018-11-27 Celgene Corporation Methods of treatment of malignancies
JP6682043B2 (ja) * 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤

Also Published As

Publication number Publication date
EP4210766A1 (en) 2023-07-19
WO2022056453A1 (en) 2022-03-17
US20230405135A1 (en) 2023-12-21
TW202227138A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
EA202090495A1 (ru) Производные 6-амино-7,9-дигидро-8h-пурин-8-она в качестве иммуностимулирующих агонистов toll-подобного рецептора 7 (tlr7)
EA202190471A1 (ru) Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
EA202090410A1 (ru) АГОНИСТЫ Toll-ПОДОБНОГО РЕЦЕПТОРА 7 (TLR7), ИМЕЮЩИЕ ПИРИДИНОВЫЙ ИЛИ ПИРАЗИНОВЫЙ ФРАГМЕНТ, ИХ КОНЪЮГАТЫ, ПРИМЕНЕНИЯ И СПОСОБЫ С НИМИ
EA201890450A1 (ru) Циклические динуклеотидные соединения в качестве агонистов sting
PE20181067A1 (es) Conjugados de anticuerpo-farmaco de pirrolobenzodiazepina y metodos de uso
AR077701A1 (es) Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
PE20191235A1 (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
ECSP21035414A (es) Conjugados de fármaco-anticuerpo
AR114738A1 (es) Moduladores de la expresión de pnpla3
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
EA202192433A1 (ru) Соединения, полезные в терапии вич
MY193343A (en) Biosynthetic heparin
CO2018010787A2 (es) Compuesto de griseofulvina
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2023015423A (es) Ligando de acido nucleico y conjugado, metodo de preparacion y uso del mismo.
ES2540327T3 (es) Derivados de 8-hidroxiquinolin-7-carboxamida terciaria y usos de los mismos
GT200100251A (es) Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida
EA202190298A1 (ru) Циклические динуклеотиды в качестве агонистов sting
CU20220052A7 (es) Derivados de hidroquinona disustituidos en 2,5 o 2,6 con un grupo carboxi, sulfo o amido útiles como medicamentos
AR123512A1 (es) Conjugados terapéuticos
AR104895A1 (es) Conjugados fluorescentes

Legal Events

Date Code Title Description
FB Suspension of granting procedure